{"id":708061,"date":"2026-06-18T05:17:51","date_gmt":"2026-06-18T03:17:51","guid":{"rendered":"https:\/\/www.dynseo.com\/neuroleptiques-et-demence-les-contre-indications-que-tout-soignant-doit-connaitre-dynseo\/"},"modified":"2026-06-18T05:20:53","modified_gmt":"2026-06-18T03:20:53","slug":"neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know","status":"publish","type":"post","link":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/","title":{"rendered":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Article HTML&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;Contenu&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;HTML import\u00e9&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<style type=\"text\/css\">\n:root{\n  --bleu:#5e5ed7;--bleu-soft:#eeeeff;--bleu2:#5268c9;--bleu2-soft:#e8ecfa;\n  --vert:#a9e2e4;--vert-soft:#e4f5f6;--jaune:#ffeca7;--jaune-soft:#fff8e0;\n  --rose:#e73469;--rose-soft:#fde8ef;--dark:#1a1a2e;--radius:20px;\n  --shadow:0 4px 20px rgba(0,0,0,.05);\n}\n.dbi-art-b4c810 * {margin:0;padding:0;box-sizing:border-box;}\n.dbi-art-b4c810 {scroll-behavior:smooth;}\n.dbi-art-b4c810 {font-family:'Poppins',-apple-system,BlinkMacSystemFont,sans-serif;line-height:1.75;color:#333;background:#fff;overflow-x:hidden;}\n.dbi-art-b4c810 img {max-width:100%;height:auto;display:block;}\n.dbi-art-b4c810 a {color:inherit;text-decoration:none;}\n.dbi-art-b4c810 .container {max-width:820px;margin:0 auto;padding:0 24px;}\n.dbi-art-b4c810 .article-hero {background:var(--rose-soft);padding:70px 24px 0;position:relative;overflow:visible;}\n.dbi-art-b4c810 .article-hero-curve {position:absolute;bottom:-2px;left:0;right:0;width:100%;height:60px;background:#fff;border-radius:50% 50% 0 0;z-index:4;}\n.dbi-art-b4c810 .article-hero-inner {max-width:820px;margin:0 auto;position:relative;z-index:3;padding-bottom:80px;}\n.dbi-art-b4c810 .article-breadcrumb {font-size:12px;color:var(--bleu);margin-bottom:20px;}\n.dbi-art-b4c810 .article-breadcrumb a {color:var(--bleu);border-bottom:1px solid rgba(94,94,215,.25);transition:border-color .2s;}\n.dbi-art-b4c810 .article-breadcrumb a:hover {border-bottom-color:var(--bleu);}\n.dbi-art-b4c810 .article-category {display:inline-block;font-family:'Montserrat',sans-serif;font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:var(--rose);background:#fff;border-radius:30px;padding:7px 18px;margin-bottom:16px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .article-hero h1 {font-family:'Montserrat',sans-serif;font-size:clamp(24px,4vw,34px);font-weight:800;color:var(--dark);line-height:1.3;margin-bottom:16px;}\n.dbi-art-b4c810 .article-hero h1 .hl {display:inline;color:#fff;background:var(--rose);border-radius:8px;padding:1px 12px 3px;}\n.dbi-art-b4c810 .article-meta {font-size:13px;color:#555;display:flex;gap:20px;flex-wrap:wrap;align-items:center;}\n.dbi-art-b4c810 .article-meta span {display:flex;align-items:center;gap:6px;}\n.dbi-art-b4c810 .article-body {padding:50px 0 60px;}\n.dbi-art-b4c810 .article-body p {margin-bottom:20px;text-align:justify;font-size:15px;color:#444;line-height:1.85;}\n.dbi-art-b4c810 .article-body strong {color:var(--dark);font-weight:600;}\n.dbi-art-b4c810 .article-body h2 {font-family:'Montserrat',sans-serif;font-size:clamp(20px,3vw,26px);font-weight:800;color:var(--dark);margin:50px 0 18px;line-height:1.3;padding-bottom:10px;border-bottom:3px solid var(--vert);}\n.dbi-art-b4c810 .article-body h3 {font-family:'Montserrat',sans-serif;font-size:clamp(17px,2.5vw,20px);font-weight:700;color:var(--bleu);margin:35px 0 14px;line-height:1.35;}\n.dbi-art-b4c810 .key-points {background:var(--vert-soft);padding:30px 32px;border-radius:var(--radius);margin:35px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .key-points h3 {font-family:'Montserrat',sans-serif;font-size:17px;font-weight:800;color:var(--bleu2);margin:0 0 14px;}\n.dbi-art-b4c810 .key-points ul {list-style:none;padding:0;margin:0;}\n.dbi-art-b4c810 .key-points li {margin:10px 0;padding-left:26px;position:relative;color:#444;font-size:14px;line-height:1.7;}\n.dbi-art-b4c810 .key-points li::before {content:'2713';position:absolute;left:0;color:var(--bleu);font-weight:800;}\n.dbi-art-b4c810 .info-box {background:var(--bleu-soft);padding:28px 30px;border-radius:var(--radius);margin:35px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .info-box p {font-size:14px;color:#444;margin-bottom:10px;}\n.dbi-art-b4c810 .info-box p:last-child {margin-bottom:0;}\n.dbi-art-b4c810 .info-box strong {color:var(--dark);}\n.dbi-art-b4c810 .article-quote {background:var(--jaune-soft);padding:32px 30px;border-radius:var(--radius);margin:40px 0;box-shadow:var(--shadow);position:relative;}\n.dbi-art-b4c810 .article-quote::before {content:'201C';font-size:100px;position:absolute;top:-20px;left:20px;font-family:Georgia,serif;color:var(--jaune);opacity:.5;}\n.dbi-art-b4c810 .article-quote p {font-size:14px;font-style:italic;color:#444;position:relative;z-index:1;margin-bottom:10px;text-align:left;}\n.dbi-art-b4c810 .article-quote .quote-author {font-family:'Montserrat',sans-serif;font-weight:800;font-style:normal;color:var(--bleu);font-size:13px;}\n.dbi-art-b4c810 .numbered-list {counter-reset:steps;margin:25px 0;padding:0;list-style:none;}\n.dbi-art-b4c810 .numbered-list li {counter-increment:steps;margin:16px 0;padding:18px 22px 18px 70px;border-radius:var(--radius);box-shadow:var(--shadow);position:relative;font-size:14px;color:#444;line-height:1.7;}\n.dbi-art-b4c810 .numbered-list li:nth-child(1) {background:var(--vert-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(2) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(3) {background:var(--jaune-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(4) {background:var(--rose-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(5) {background:var(--bleu2-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(6) {background:var(--vert-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(7) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .numbered-list li::before {content:counter(steps);position:absolute;left:18px;top:50%;transform:translateY(-50%);width:38px;height:38px;border-radius:12px;background:rgba(255,255,255,.85);font-family:'Montserrat',sans-serif;font-weight:800;font-size:16px;display:flex;align-items:center;justify-content:center;color:var(--bleu);}\n.dbi-art-b4c810 .numbered-list li strong {color:var(--dark);}\n.dbi-art-b4c810 .comparison-table {width:100%;border-collapse:separate;border-spacing:0;border-radius:var(--radius);overflow:hidden;box-shadow:var(--shadow);margin:30px 0;}\n.dbi-art-b4c810 .comparison-table thead th {background:var(--bleu);color:#fff;font-family:'Montserrat',sans-serif;font-size:13px;font-weight:700;padding:16px 18px;text-align:left;}\n.dbi-art-b4c810 .comparison-table tbody td {padding:14px 18px;font-size:13px;color:#444;vertical-align:top;}\n.dbi-art-b4c810 .comparison-table tbody tr:nth-child(odd) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .comparison-table tbody tr:nth-child(even) {background:var(--vert-soft);}\n.dbi-art-b4c810 .comparison-table tbody td:first-child {font-weight:600;color:var(--dark);}\n.dbi-art-b4c810 .danger-table thead th {background:var(--rose);}\n.dbi-art-b4c810 .case-study {background:#fff;padding:30px 32px;border-radius:var(--radius);margin:30px 0;box-shadow:0 6px 25px rgba(0,0,0,.07);}\n.dbi-art-b4c810 .case-study-header {display:flex;align-items:center;gap:14px;margin-bottom:16px;}\n.dbi-art-b4c810 .case-study-emoji {font-size:2.2rem;}\n.dbi-art-b4c810 .case-study-label {font-family:'Montserrat',sans-serif;font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;margin-bottom:2px;}\n.dbi-art-b4c810 .case-study-title {font-family:'Montserrat',sans-serif;font-size:17px;font-weight:800;color:var(--dark);}\n.dbi-art-b4c810 .case-study p {font-size:14px;color:#444;line-height:1.75;margin-bottom:12px;}\n.dbi-art-b4c810 .case-study p:last-child {margin-bottom:0;}\n.dbi-art-b4c810 .case-study-result {background:var(--vert-soft);padding:16px 20px;border-radius:14px;margin-top:16px;}\n.dbi-art-b4c810 .case-study-result p {margin:0;font-size:13px;color:var(--dark);}\n.dbi-art-b4c810 .case-study:nth-child(odd) .case-study-label {color:var(--bleu);}\n.dbi-art-b4c810 .case-study:nth-child(even) .case-study-label {color:var(--rose);}\n.dbi-art-b4c810 .case-study:nth-child(even) .case-study-result {background:var(--bleu-soft);}\n.dbi-art-b4c810 .error-box {background:var(--rose-soft);padding:24px 28px;border-radius:var(--radius);margin:20px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .error-box-title {font-family:'Montserrat',sans-serif;font-size:15px;font-weight:800;color:var(--rose);margin-bottom:8px;}\n.dbi-art-b4c810 .error-box p {font-size:14px;color:#444;margin:0;line-height:1.7;}\n.dbi-art-b4c810 .error-fix {background:var(--vert-soft);padding:24px 28px;border-radius:var(--radius);margin:8px 0 30px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .error-fix-title {font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;color:var(--bleu);margin-bottom:6px;}\n.dbi-art-b4c810 .error-fix p {font-size:14px;color:#444;margin:0;line-height:1.7;}\n.dbi-art-b4c810 .cta-box {background:linear-gradient(135deg,var(--bleu) 0%,var(--bleu2) 100%);padding:40px 36px;border-radius:22px;margin:50px 0;text-align:center;color:#fff;}\n.dbi-art-b4c810 .cta-box h3 {font-family:'Montserrat',sans-serif;font-size:22px;font-weight:800;margin-bottom:12px;}\n.dbi-art-b4c810 .cta-box p {font-size:14px;color:rgba(255,255,255,.85);margin-bottom:24px;max-width:550px;margin-left:auto;margin-right:auto;}\n.dbi-art-b4c810 .cta-box .cta-buttons {display:flex;justify-content:center;gap:14px;flex-wrap:wrap;}\n.dbi-art-b4c810 .btn-cta-white {display:inline-block;padding:14px 34px;border-radius:30px;font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;background:#fff;color:var(--bleu);transition:all .3s ease;}\n.dbi-art-b4c810 .btn-cta-white:hover {background:var(--rose);color:#fff;transform:translateY(-2px);}\n.dbi-art-b4c810 .btn-cta-outline {display:inline-block;padding:14px 34px;border-radius:30px;font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;border:2px solid rgba(255,255,255,.5);color:#fff;transition:all .3s ease;}\n.dbi-art-b4c810 .btn-cta-outline:hover {border-color:#fff;background:rgba(255,255,255,.1);}\n.dbi-art-b4c810 .internal-link {display:flex;align-items:center;gap:20px;background:var(--jaune-soft);padding:24px 28px;border-radius:var(--radius);box-shadow:var(--shadow);margin:40px 0;transition:all .3s ease;}\n.dbi-art-b4c810 .internal-link:hover {transform:translateY(-3px);box-shadow:0 8px 28px rgba(0,0,0,.1);}\n.dbi-art-b4c810 .internal-link-icon {font-size:2.5rem;flex-shrink:0;}\n.dbi-art-b4c810 .internal-link-content {flex:1;min-width:0;}\n.dbi-art-b4c810 .internal-link-label {font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:var(--rose);margin-bottom:4px;}\n.dbi-art-b4c810 .internal-link-title {font-family:'Montserrat',sans-serif;font-size:16px;font-weight:800;color:var(--dark);margin-bottom:4px;}\n.dbi-art-b4c810 .internal-link-desc {font-size:13px;color:#555;}\n.dbi-art-b4c810 .internal-link-arrow {font-size:1.5rem;color:var(--bleu);flex-shrink:0;transition:transform .3s;}\n.dbi-art-b4c810 .internal-link:hover .internal-link-arrow {transform:translateX(4px);}\n.dbi-art-b4c810 .article-tags {display:flex;flex-wrap:wrap;gap:8px;margin:40px 0 20px;padding-top:30px;border-top:2px solid #f0f0f0;}\n.dbi-art-b4c810 .article-tag {display:inline-block;padding:6px 16px;border-radius:30px;font-size:12px;font-weight:600;transition:all .2s;}\n.dbi-art-b4c810 .article-tag:nth-child(odd) {color:var(--bleu);background:var(--bleu-soft);}\n.dbi-art-b4c810 .article-tag:nth-child(even) {color:var(--rose);background:var(--rose-soft);}\n.dbi-art-b4c810 .article-tag:hover {transform:translateY(-2px);box-shadow:0 3px 10px rgba(0,0,0,.08);}\n.dbi-art-b4c810 .toc {background:var(--bleu2-soft);padding:28px 30px;border-radius:var(--radius);margin:0 0 40px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .toc h4 {font-family:'Montserrat',sans-serif;font-size:14px;font-weight:800;color:var(--dark);margin-bottom:14px;}\n.dbi-art-b4c810 .toc ol {padding-left:20px;margin:0;}\n.dbi-art-b4c810 .toc li {margin:8px 0;font-size:13px;}\n.dbi-art-b4c810 .toc a {color:var(--bleu);font-weight:600;border-bottom:1px solid transparent;transition:border-color .2s;}\n.dbi-art-b4c810 .toc a:hover {border-bottom-color:var(--bleu);}\n.dbi-art-b4c810 .alerte-box {background:#fff0f0;border-left:5px solid var(--rose);padding:24px 28px;border-radius:0 var(--radius) var(--radius) 0;margin:30px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .alerte-box-title {font-family:'Montserrat',sans-serif;font-size:16px;font-weight:800;color:var(--rose);margin-bottom:10px;}\n.dbi-art-b4c810 .alerte-box p {font-size:14px;color:#444;margin:0;line-height:1.75;}\n@media(max-width:600px) {\n.dbi-art-b4c810 .article-hero {padding:50px 16px 0;}\n.dbi-art-b4c810 .article-hero-curve {height:40px;}\n.dbi-art-b4c810 .article-hero-inner {padding-bottom:60px;}\n.dbi-art-b4c810 .article-meta {flex-direction:column;gap:8px;}\n.dbi-art-b4c810 .container {padding:0 16px;}\n.dbi-art-b4c810 .article-body p {font-size:14px;}\n.dbi-art-b4c810 .key-points, .dbi-art-b4c810 .info-box, .dbi-art-b4c810 .error-box, .dbi-art-b4c810 .error-fix {padding:24px 20px;}\n.dbi-art-b4c810 .article-quote {padding:24px 20px;}\n.dbi-art-b4c810 .case-study {padding:24px 20px;}\n.dbi-art-b4c810 .numbered-list li {padding:16px 16px 16px 60px;}\n.dbi-art-b4c810 .cta-box {padding:30px 20px;}\n.dbi-art-b4c810 .cta-box h3 {font-size:19px;}\n.dbi-art-b4c810 .cta-box .cta-buttons {flex-direction:column;max-width:260px;margin-left:auto;margin-right:auto;}\n.dbi-art-b4c810 .btn-cta-white, .dbi-art-b4c810 .btn-cta-outline {width:100%;text-align:center;padding:13px 24px;font-size:13px;}\n.dbi-art-b4c810 .internal-link {flex-direction:column;text-align:center;gap:12px;padding:22px 18px;}\n.dbi-art-b4c810 .internal-link-arrow {transform:rotate(90deg);}\n.dbi-art-b4c810 .internal-link:hover .internal-link-arrow {transform:rotate(90deg) translateX(4px);}\n.dbi-art-b4c810 .comparison-table {font-size:12px;}\n.dbi-art-b4c810 .comparison-table thead th, .dbi-art-b4c810 .comparison-table tbody td {padding:10px 12px;}\n.dbi-art-b4c810 .toc {padding:22px 20px;}\n}<\/p>\n<\/style>\n<p><script type=\"application\/ld+json\">\n{\n  \"@context\":\"https:\/\/schema.org\",\n  \"@type\":\"Article\",\n  \"headline\":\"Neuroleptiques et d\u00e9mence : les contre-indications que tout soignant doit conna\u00eetre\",\n  \"description\":\"Guide complet sur les risques des neuroleptiques dans les d\u00e9mences en EHPAD : contre-indications absolues (DCL), alternatives non m\u00e9dicamenteuses, protocoles de s\u00e9curit\u00e9 au transfert.\",\n  \"author\":{\"@type\":\"Organization\",\"name\":\"DYNSEO\",\"url\":\"https:\/\/www.dynseo.com\"},\n  \"publisher\":{\"@type\":\"Organization\",\"name\":\"DYNSEO\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/www.dynseo.com\/wp-content\/uploads\/2021\/03\/logo-dynseo.png\"}},\n  \"datePublished\":\"2026-03-06\",\n  \"dateModified\":\"2026-03-06\",\n  \"mainEntityOfPage\":\"https:\/\/www.dynseo.com\/neuroleptiques-demence-contre-indications-ehpad\/\"\n}\n<\/script><\/p>\n<div class=\"dbi-art-b4c810\">\n<header class=\"article-hero\">\n<div class=\"article-hero-inner\">\n<nav class=\"article-breadcrumb\">\n      <a href=\"https:\/\/www.dynseo.com\/en\/\">Home<\/a> &rsaquo;<br \/>\n      <a href=\"https:\/\/www.dynseo.com\/en\/healthcare-professionals\/\">Professionals<\/a> &rsaquo;<br \/>\n      Neuroleptics and dementia in Nursing home<br \/>\n    <\/nav>\n<p>    <span class=\"article-category\">&#x26A0;&#xFE0F; MEDICATION SAFETY<\/span><\/p>\n<h1>Neuroleptics and dementia&nbsp;: the <span class=\"hl\">absolute contraindications<\/span> that every caregiver must know<\/h1>\n<div class=\"article-meta\">\n      <span>&#x1F4C5; March 2026<\/span><br \/>\n      <span>&#x23F1; 17 min read<\/span><br \/>\n      <span>&#x1F9D1;&#x200D;&#x2695;&#xFE0F; By the DYNSEO team<\/span>\n    <\/div>\n<\/p><\/div>\n<div class=\"article-hero-curve\"><\/div>\n<\/header>\n<div class=\"container\">\n<article class=\"article-body\">\n<div class=\"toc\">\n<h4>&#x1F4D1; Table of contents<\/h4>\n<ol>\n<li><a href=\"#pourquoi\">Why neuroleptics are so often prescribed in Nursing home<\/a><\/li>\n<li><a href=\"#mecanisme\">How neuroleptics act on the demented brain<\/a><\/li>\n<li><a href=\"#dcl-danger\">DCL: the absolute and potentially fatal contraindication<\/a><\/li>\n<li><a href=\"#alzheimer\">Alzheimer&#8217;s disease and neuroleptics: underestimated risks<\/a><\/li>\n<li><a href=\"#dft\">DFT and other dementias: what the literature says<\/a><\/li>\n<li><a href=\"#autres-molecules\">Other risky molecules in dementias<\/a><\/li>\n<li><a href=\"#alternatives\">Non-drug alternatives to neuroleptics<\/a><\/li>\n<li><a href=\"#protocole-transfert\">Securing transfers: the medication liaison sheet<\/a><\/li>\n<li><a href=\"#role-soignant\">The caregiver&#8217;s role in medication vigilance<\/a><\/li>\n<li><a href=\"#cas-pratiques\">Practical cases: spotting and alerting<\/a><\/li>\n<\/ol>\n<\/div>\n<pee>In France, neuroleptics are among the most frequently prescribed medications for elderly people living in Nursing home. According to data from the Haute Autorit\u00e9 de Sant\u00e9, more than 20&nbsp;% of demented residents receive an antipsychotic, while official recommendations limit their use to very specific and short-term situations. This gap between recommendations and practices has real consequences on the health, quality of life, and safety of residents.<\/pee>\n<pee>For the majority of dementias, neuroleptics present serious side effects \u2014 falls, confusion, excessive sedation, acceleration of cognitive decline. In Lewy body dementia, they can be <strong>directly fatal<\/strong>. In frontotemporal dementia, they are often ineffective on target behaviors while adding metabolic and neurological risks.<\/pee>\n<pee>This guide is aimed at all professionals involved in the medication circuit in Nursing home \u2014 nurses, nursing assistants, coordinating doctors, pharmacists \u2014 with a clear objective&nbsp;: <strong>to know the risks, identify warning signals, and act to secure residents<\/strong>.<\/pee>\n<div class=\"alerte-box\">\n<div class=\"alerte-box-title\">&#x1F6A8; Important prior warning<\/div>\n<pee>This article is a training and awareness tool. It does not replace the opinion of the prescribing doctor. No decision to stop or modify a treatment should be made without a medical prescription. However, <strong>every caregiving team not only has the right but the duty to alert the coordinating doctor<\/strong> if they observe signs indicative of an adverse reaction to a medication.<\/pee>\n<\/div>\n<h2 id=\"pourquoi\">1. Why neuroleptics are so often prescribed in Nursing homes<\/h2>\n<pee>Neuroleptics \u2014 also called antipsychotics \u2014 are medications originally developed to treat schizophrenia and psychoses. Their effectiveness on hallucinations and delusional thoughts in these pathologies has led to their widespread use in behavioral disorders of dementia: agitation, aggression, nighttime wandering, hallucinations.<\/pee>\n<pee>Several factors explain their frequent prescription in Nursing homes. First, the <strong>pressure of disruptive behaviors<\/strong>: the agitation of a resident in a Nursing home not only affects the resident themselves, it disrupts other residents, exhausts the caregiving team, and generates crisis situations that need to be addressed quickly. Neuroleptics offer an immediate response, which non-drug approaches, more effective in the long term, do not always allow.<\/pee>\n<pee>Next, the <strong>lack of training on alternatives<\/strong>: many teams in Nursing homes do not have the necessary tools and protocols to manage behavioral disorders without quickly resorting to medication. Training in behavioral approaches, validation, and environmental adaptation remains insufficient in many facilities.<\/pee>\n<pee>Finally, the <strong>pressure from families<\/strong>: relatives exhausted by their parent&#8217;s agitation may explicitly request a sedative treatment, putting the doctor in a delicate position. Prescribing a neuroleptic may appear as a response to a legitimate request for relief.<\/pee>\n<div class=\"info-box\">\n  <pee><strong>&#x1F4CA; What the data says.<\/strong> The HAS reminds in its recommendations that neuroleptics are indicated in BPSD (Behavioral and Psychological Symptoms of Dementia) only as a second-line treatment, after failure of non-drug approaches, in cases of severe symptoms presenting a risk to the resident or their surroundings, for the shortest duration possible (a few weeks), with regular reevaluation. In practice, these conditions are not always respected: treatments initially prescribed for an acute crisis sometimes persist for months or years without reevaluation.<\/pee>\n<\/div>\n<h2 id=\"mecanisme\">2. How neuroleptics act on the demented brain<\/h2>\n<pee>Neuroleptics primarily act by blocking D2 dopamine receptors in the brain. This blockage reduces dopaminergic activity in the mesolimbic circuits, which explains their antipsychotic effect. However, this same blockage in other brain circuits generates unwanted effects: blockage of dopamine receptors in the nigrostriatal pathways (extrapyramidal syndrome), in the hypothalamus (metabolic and hormonal disturbances), and in other neurotransmission systems (antihistaminic, anticholinergic, antiadrenergic).<\/pee>\n<pee>In elderly demented individuals, these unwanted effects are amplified for several reasons. Aging reduces brain reserve and the ability to adapt to neurochemical disturbances. Frequent polypharmacy in the elderly multiplies interactions. And certain neurodegenerative pathologies \u2014 particularly MCI \u2014 create a specific vulnerability to dopaminergic molecules.<\/pee>\n<h3>Common unwanted effects in all dementias<\/h3>\n<pee>Even in the most legitimate indications, neuroleptics in demented individuals expose them to a range of documented unwanted effects: <strong>excessive sedation<\/strong> that worsens cognitive and functional deficits, <strong>extrapyramidal syndrome<\/strong> (rigidity, bradykinesia, gait disturbances, increased risk of falls), <strong>orthostatic hypotension<\/strong> (dizziness upon standing, falls), <strong>prolongation of the QT interval<\/strong> (risk of cardiac arrhythmia), <strong>anticholinergic effects<\/strong> (dry mouth, constipation, urinary retention, worsened confusion), and <strong>metabolic syndrome<\/strong> (weight gain, diabetes).<\/pee>\n<pee>A meta-analysis published in the <em>British Medical Journal<\/em> confirmed that antipsychotics increase the risk of mortality in elderly demented individuals, regardless of the underlying pathology. This risk is approximately 1.5 to 1.7 times that observed without antipsychotics. It is based on this data that European and American regulatory agencies have issued official warnings regarding the use of antipsychotics in dementias.<\/pee>\n<h2 id=\"dcl-danger\">3. MCI: the absolute and potentially fatal contraindication<\/h2>\n<pee>Lewy body dementia represents the most critical case in terms of medication safety. Sensitivity to neuroleptics in MCI is not just another unwanted effect on a long list: it is an <strong>unpredictable, rapid, and potentially fatal<\/strong> reaction that occurs in 30 to 50% of exposed patients.<\/pee>\n<h3>The hypersensitivity syndrome to neuroleptics in MCI<\/h3>\n<pee>This syndrome typically manifests within hours or days following the introduction of the neuroleptic. It is characterized by a <strong>brutal and severe worsening of confusion<\/strong> (the resident who was partially autonomous becomes completely disoriented), <strong>intense muscle rigidity<\/strong> sometimes accompanied by abnormal postures, <strong>hyperthermia<\/strong>, <strong>blood pressure instability<\/strong>, and consciousness disturbances that can lead to coma. Without rapid medical intervention, this condition can be fatal.<\/pee>\n<pee>The mechanism is related to the dopaminergic deficiency specific to MCI. The dopaminergic neurons in the substantia nigra are already severely affected by Lewy bodies. Blocking the residual dopamine receptors with a neuroleptic amounts to cutting off the little dopaminergic signal still available in these circuits, leading to a sudden neurological collapse.<\/pee>\n<h3>All neuroleptics are concerned<\/h3>\n<pee>A common mistake is to believe that only &#8220;typical&#8221; neuroleptics (haloperidol, chlorpromazine) are dangerous in MCI and that &#8220;atypical&#8221; neuroleptics (risperidone, olanzapine) are safe. This distinction is <strong>false and dangerous<\/strong>: atypical neuroleptics present the same risk of hypersensitivity in MCI, even if their overall profile of unwanted effects differs. Risperidone and olanzapine in particular have been associated with severe reactions in MCI.<\/pee>\n<pee>Quetiapine (Seroquel) is sometimes mentioned as being better tolerated in MCI, due to its different receptor binding profile. It may be used in certain cases by specialized teams, at very low doses and with close monitoring. However, it can in no way be considered &#8220;risk-free&#8221; in MCI and must always be subject to a specialized medical decision.<\/pee>\n<div class=\"alerte-box\">\n<div class=\"alerte-box-title\">&#x1F6A8; Absolute contraindication \u2014 to memorize and to transmit<\/div>\n<pee>Classic neuroleptics and the majority of atypical neuroleptics are <strong>formally contraindicated<\/strong> in Lewy body dementia. This contraindication must be clearly stated in the care file, in any transfer document, and in the resident&#8217;s health booklet. It must be known by the entire care team, by the family, and by any physician involved with the resident.<\/pee>\n<\/div>\n<table class=\"comparison-table danger-table\">\n<thead>\n<tr>\n<th>Molecule<\/th>\n<th>Brand name<\/th>\n<th>DCL Risk<\/th>\n<th>Status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Haloperidol<\/td>\n<td>Haldol<\/td>\n<td>Severe hypersensitivity syndrome, mortality<\/td>\n<td>CONTRAINDICATED<\/td>\n<\/tr>\n<tr>\n<td>Chlorpromazine<\/td>\n<td>Largactil<\/td>\n<td>Hypersensitivity syndrome, major extrapyramidal effects<\/td>\n<td>CONTRAINDICATED<\/td>\n<\/tr>\n<tr>\n<td>Tiapride<\/td>\n<td>Tiapridal<\/td>\n<td>Severe extrapyramidal syndrome, cognitive worsening<\/td>\n<td>CONTRAINDICATED<\/td>\n<\/tr>\n<tr>\n<td>Risperidone<\/td>\n<td>Risperdal<\/td>\n<td>Hypersensitivity, Stroke, increased mortality<\/td>\n<td>CONTRAINDICATED<\/td>\n<\/tr>\n<tr>\n<td>Olanzapine<\/td>\n<td>Zyprexa<\/td>\n<td>Hypersensitivity, deep sedation, mortality<\/td>\n<td>TO AVOID<\/td>\n<\/tr>\n<tr>\n<td>Quetiapine<\/td>\n<td>Seroquel<\/td>\n<td>Lower but real risk \u2014 specialized use only<\/td>\n<td>SPECIALIZED ADVICE REQUIRED<\/td>\n<\/tr>\n<tr>\n<td>Aripiprazole<\/td>\n<td>Abilify<\/td>\n<td>Insufficient data in DCL \u2014 to avoid as a precaution<\/td>\n<td>TO AVOID<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"alzheimer\">4. Alzheimer&#8217;s disease and neuroleptics: underestimated risks<\/h2>\n<pee>In Alzheimer&#8217;s disease, neuroleptics are not absolutely contraindicated as in DCL, but they still present a significant risk profile that justifies reserving them for the most severe situations, as a last resort, and for short durations.<\/pee>\n<h3>Modest efficacy on target symptoms<\/h3>\n<pee>Clinical studies on antipsychotics in Alzheimer&#8217;s BPSD show modest efficacy, primarily limited to severe aggression and psychotic symptoms (hallucinations, delusions). They have no demonstrated efficacy on wandering, pacing, apathy, or sleep disorders \u2014 yet these are among the most frequent reasons for prescription in real practice. The use of neuroleptics for these symptoms is therefore both risky and poorly supported by evidence.<\/pee>\n<h3>Acceleration of cognitive decline<\/h3>\n<pee>Several longitudinal studies have shown that prolonged use of antipsychotics in Alzheimer&#8217;s disease is associated with an <strong>acceleration of cognitive decline<\/strong> compared to untreated residents. This effect adds to the natural progression of the disease and reduces the window of functional and relational abilities of the resident. For families seeking to maintain contact and communication with their loved one, this effect has concrete consequences on the quality of visits.<\/pee>\n<h3>The risk of Stroke<\/h3>\n<pee>Atypical antipsychotics (risperidone, olanzapine, aripiprazole) have been the subject of regulatory alerts due to an <strong>increased risk of Stroke<\/strong> in elderly demented individuals. This risk, documented in controlled clinical trials, has led to an official warning against their off-label use in dementias. Risperidone is the only antipsychotic with marketing authorization for BPSD in Europe, under very strict conditions and for a maximum duration of 6 weeks.<\/pee>\n<h2 id=\"dft\">5. DFT and other dementias: what the literature says<\/h2>\n<pee>In frontotemporal dementia, neuroleptics are often prescribed to manage disinhibition and agitation. Their efficacy on these frontal behaviors is, however, very limited, or even null, for a simple neurobiological reason: the disinhibited behaviors of DFT are not mediated by the mesolimbic dopaminergic circuits on which antipsychotics act, but by the degeneration of fronto-striatal serotonergic and glutamatergic circuits.<\/pee>\n<pee>Serotonin reuptake inhibitors (SRIs, such as sertraline or fluoxetine) have shown modest but real efficacy on disinhibition and hyperphagia in DFTvc, with a side effect profile much more favorable than antipsychotics. They represent a medication alternative to be evaluated with the coordinating physician before resorting to neuroleptics.<\/pee>\n<pee>In vascular dementia, neuroleptics present the same general risks as in Alzheimer&#8217;s, with an additionally potentially increased cardiovascular risk due to the vascular comorbidities usually associated. In PSP, the profile of subcortical dopaminergic denervation is similar to that of DCL, which justifies great caution regarding neuroleptics in this pathology as well.<\/pee>\n<h2 id=\"autres-molecules\">6. Other risky molecules in dementias<\/h2>\n<pee>Neuroleptics are not the only molecules to monitor in dementias. Many commonly used medications in geriatrics present problematic side effect profiles in individuals already weakened by a neurodegenerative condition.<\/pee>\n<table class=\"comparison-table\">\n<thead>\n<tr>\n<th>Drug class<\/th>\n<th>Common medications<\/th>\n<th>Main risk in dementias<\/th>\n<th>Particular vigilance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Urinary anticholinergics<\/td>\n<td>Oxybutynin (Ditropan), solifenacin (V\u00e9sicare)<\/td>\n<td>Worsening confusion, hallucinations, memory disorders<\/td>\n<td>DCL, Alzheimer&#8217;s<\/td>\n<\/tr>\n<tr>\n<td>Sedative antihistamines<\/td>\n<td>Hydroxyzine (Atarax), diphenhydramine<\/td>\n<td>Anticholinergic effects, sedation, confusion<\/td>\n<td>All dementias<\/td>\n<\/tr>\n<tr>\n<td>Benzodiazepines<\/td>\n<td>Diazepam, lorazepam, alprazolam, zolpidem<\/td>\n<td>Falls, excessive sedation, worsening fluctuations (DCL)<\/td>\n<td>Particularly DCL<\/td>\n<\/tr>\n<tr>\n<td>Tricyclic antidepressants<\/td>\n<td>Amitriptyline (Laroxyl), clomipramine<\/td>\n<td>Anticholinergic effects, confusion, cardiotoxicity<\/td>\n<td>DCL, frail elderly people<\/td>\n<\/tr>\n<tr>\n<td>Antispasmodics<\/td>\n<td>Tiemonium (Visc\u00e9ralgine), scopolamine<\/td>\n<td>Anticholinergic effects, acute confusion<\/td>\n<td>All dementias<\/td>\n<\/tr>\n<tr>\n<td>Corticosteroids<\/td>\n<td>Prednisone, methylprednisolone<\/td>\n<td>Acute confusion, corticosteroid-induced psychosis, agitation<\/td>\n<td>Especially if prolonged treatment<\/td>\n<\/tr>\n<tr>\n<td>Opioids<\/td>\n<td>Morphine, tramadol, codeine<\/td>\n<td>Confusion, hallucinations, sedation, falls<\/td>\n<td>Necessary but to be dosed carefully<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"info-box\">\n  <pee><strong>&#x1F4A1; The total anticholinergic score.<\/strong> Many residents with dementia are exposed to multiple medications with moderate anticholinergic effects. The effect of these molecules is cumulative: a high anticholinergic score (sum of the burdens of each medication) is associated with a significantly increased risk of confusion, cognitive decline, and falls. Tools like the Anticholinergic Cognitive Burden (ACB) scale allow doctors and pharmacists to assess this overall risk. In units where this score is calculated regularly, a reduction in hospitalizations for acute confusion is observed.<\/pee>\n<\/div>\n<h2 id=\"alternatives\">7. Non-pharmacological alternatives to neuroleptics<\/h2>\n<pee>The best response to behavioral disorders in dementia is non-pharmacological. This is the main conclusion of all good practice recommendations, both French and international. Non-pharmacological approaches have shown equivalent or superior efficacy to neuroleptics on BPSD, with an infinitely more favorable risk profile.<\/pee>\n<h3>Functional analysis of behavior<\/h3>\n<pee>Before addressing a disruptive behavior, it is essential to understand it first. Functional analysis involves identifying the <strong>antecedents, the behavior itself, and its consequences<\/strong> (ABC method \u2014 Antecedents, Behavior, Consequences). Often, a behavior of agitation is a response to an unmet need: unexpressed pain, physical discomfort (cold, hunger, need to urinate), overly stimulating environment, feeling of insecurity. Addressing the underlying need is more effective than sedating the reaction.<\/pee>\n<ol class=\"numbered-list\">\n<li><strong>Adapting the sensory environment<\/strong> &mdash; reducing noise, visual agitation, adjusting lighting, providing secure walking spaces. A calm and predictable environment significantly reduces agitation in all types of dementia.<\/li>\n<li><strong>Music therapy<\/strong> &mdash; listening to familiar and appreciated music reduces agitation, anxiety, and disruptive behaviors, with strong evidence in Alzheimer&#8217;s. Active music (percussion, singing) is particularly effective in frontotemporal dementia and mild cognitive impairment.<\/li>\n<li><strong>Adapted physical activity<\/strong> &mdash; regular walking, gentle exercises, tai chi reduce agitation and improve sleep quality. Physical activity also has a positive effect on cognitive decline.<\/li>\n<li><strong>Sensory approaches<\/strong> &mdash; hand massage, aromatherapy, Snoezelen, warm baths. These approaches mobilize non-cognitive sensory pathways that remain accessible even in advanced stages of dementia.<\/li>\n<li><strong>Validation and appropriate communication<\/strong> &mdash; responding to emotions rather than content, not confronting reality, maintaining a calm and caring presence. These techniques sustainably reduce anxiety and agitation when practiced consistently by the entire team.<\/li>\n<li><strong>Adapted cognitive stimulation<\/strong> &mdash; offering activities related to residual capacities maintains engagement and reduces wandering or agitation behaviors related to boredom and lack of stimulation.<\/li>\n<li><strong>Pain management<\/strong> &mdash; untreated pain is one of the leading causes of agitation in advanced dementia. Using pain assessment tools suitable for non-communicative individuals (Doloplus, ECPA) and effectively treating pain often reduces disruptive behaviors without resorting to neuroleptics.<\/li>\n<\/ol>\n<p><a href=\"https:\/\/www.dynseo.com\/en\/courses\/diseases-related-to-alzheimers-disease-understanding-distinguishing-and-adapting-practices-in-medicalized-residences-en\/\" class=\"internal-link\"><\/p>\n<div class=\"internal-link-icon\">&#x1F393;<\/div>\n<div class=\"internal-link-content\">\n<div class=\"internal-link-label\">Certified training<\/div>\n<div class=\"internal-link-title\">Diseases related to Alzheimer&#8217;s: understanding, distinguishing, and adapting practices<\/div>\n<div class=\"internal-link-desc\">DYNSEO Qualiopi training \u2014 medication safety, contraindications, non-drug approaches. Clinical cases for Nursing home teams.<\/div>\n<\/p><\/div>\n<div class=\"internal-link-arrow\">&#x2192;<\/div>\n<p><\/a><\/p>\n<h2 id=\"protocole-transfert\">8. Securing transfers: the medication liaison form<\/h2>\n<pee>The riskiest moment for a demented resident in terms of medication safety is the <strong>transfer to another facility<\/strong>: emergency room, short hospitalization, specialized consultation, respite stay. In these contexts, the professionals taking care of the resident do not know their file and may prescribe contraindicated molecules due to lack of available information.<\/pee>\n<h3>Essential elements of the liaison form<\/h3>\n<pee>Each transfer of a demented resident must be accompanied by a standardized medication liaison form containing at least: the precise diagnosis of the neurodegenerative pathology (specifying whether it is DCL, DFT, PSP, or other \u2014 not just &#8220;dementia&#8221;); the list of ongoing treatments with dosages; the list of contraindicated or at-risk medications with the resident&#8217;s pathology; allergies and history of medication reactions; and the name and number of the coordinating physician who can be contacted in case of questions.<\/pee>\n<pee>For residents with DCL in particular, this form must include a mention in red and bold characters: <strong>\u201cDEMENTIA WITH LEWY BODIES \u2014 NEUROLEPTICS FORMALLY CONTRAINDICATED \u2014 LIFE-THREATENING RISK\u201d<\/strong>. This mention must be repeated on the discharge prescription, on the accompanying letter, and on the resident&#8217;s bracelet or medical ID card if the Nursing home uses this type of support.<\/pee>\n<h3>Training the family as a safety relay<\/h3>\n<pee>Families can play a crucial role in medication safety during transfers. An informed and trained relative accompanying the resident to the emergency room can alert the emergency physician about contraindications before any prescription. This training is simple: explain to the family which molecules are dangerous for their loved one, provide them with a summary sheet to keep in their wallet or on their phone, and encourage them to show it to any new doctor.<\/pee>\n<div class=\"article-quote\">\n  <pee>\u201cMy mother was hospitalized urgently on a Sunday evening. I had the Nursing home&#8217;s form in my bag. When the emergency doctor wanted to give her Haldol to calm her down, I was able to show the form. He changed his protocol. I think it saved her life.\u201d<\/pee>\n<div class=\"quote-author\">\u2014 Daughter of a DCL resident, Nursing home Normandy<\/div>\n<\/div>\n<h2 id=\"role-soignant\">9. The role of the caregiver in medication vigilance<\/h2>\n<pee>Medication vigilance does not rely solely on doctors and pharmacists. Caregivers in daily contact with the resident are often the first to observe signs of an adverse reaction to a medication \u2014 and are best positioned to report it quickly.<\/pee>\n<h3>Warning signs to observe and report<\/h3>\n<pee>Several situations should lead the caregiver to immediately alert the coordinating nurse or doctor: a sudden worsening of confusion in the days following the introduction or increase of a medication, new muscle rigidity or a change in gait, hyperthermia without identified infection, excessive sedation making the resident difficult to wake, newly appeared repeated falls, or new hallucinations in a resident who did not previously exhibit them.<\/pee>\n<pee>Each of these signs, taken in isolation, can have multiple causes. But their <strong>appearance in the days or weeks following the introduction of a new medication<\/strong> should systematically lead to considering a medication reaction and alerting the prescriber. Mentioning the chronology (introduction of the medication D-3, appearance of the sign D0) is valuable clinical information.<\/pee>\n<h3>Transmission, an essential link<\/h3>\n<pee>An observation is only valuable if it is transmitted. The monitoring notebook, targeted transmissions, and the synthesis meeting are the channels through which caregivers&#8217; observations become actionable medical data. Training caregivers to accurately describe changes in behavior or general condition \u2014 with the time, context, and words of the resident \u2014 significantly improves the quality of collective medication monitoring.<\/pee>\n<h2 id=\"cas-pratiques\">10. Practical cases: spotting and alerting<\/h2>\n<div class=\"case-study\">\n<div class=\"case-study-header\">\n<div class=\"case-study-emoji\">&#x1F6A8;<\/div>\n<div>\n<div class=\"case-study-label\">Practical case \u2014 Critical reaction DCL<\/div>\n<div class=\"case-study-title\">Mr. Aubert, 79 years old \u2014 Haldol in the emergency room<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<pee>Mr. Aubert is a resident in a Nursing home with a DCL diagnosis made 6 months earlier. He is transferred to the emergency room on a Saturday night for intense agitation with hallucinations. The emergency doctor, lacking the complete file, prescribes IV haloperidol to calm the agitation. Six hours later, Mr. Aubert presents extreme rigidity, hyperthermia at 39.8\u00b0C, a blood pressure of 80\/50, and is no longer arousable.<\/pee>\n  <pee>The coordinating doctor, alerted by the night nurse from the Nursing home who had not received any updates, contacts the emergency room and identifies the cause. The transfer liaison form sent during the transfer did mention the DCL but the contraindication to neuroleptics was not highlighted. Mr. Aubert spends 5 days in intensive care before stabilizing.<\/pee>\n<div class=\"case-study-result\">\n    <pee>&#x26A0;&#xFE0F; <strong>Lesson:<\/strong> Following this incident, the Nursing home implemented a specific DCL transfer form with a red mention at the top of the document and trained the family to carry a medication alert card. The coordinating doctor also reported the incident to the regional gerontological network to raise awareness among emergency services.<\/pee>\n  <\/div>\n<\/div>\n<div class=\"case-study\">\n<div class=\"case-study-header\">\n<div class=\"case-study-emoji\">&#x1F9D1;&#x200D;&#x2695;&#xFE0F;<\/div>\n<div>\n<div class=\"case-study-label\">Practical case \u2014 Caregiver vigilance<\/div>\n<div class=\"case-study-title\">Mrs. Petit, 83 years old \u2014 post-prescription aggravation<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<pee>Mrs. Petit, a resident with a diagnosis of moderate Alzheimer&#8217;s disease, has been agitated for a few days. The weekend on-call doctor (not the usual coordinating doctor) prescribes risperidone 0.5 mg\/day. Three days later, the morning caregiver notes that Mrs. Petit \u201cis no longer the same\u201d: she remains seated without moving, no longer eats, and does not respond to calls. She notes the observation in the transmissions with the start date.<\/pee>\n  <pee>The coordinating nurse rereads the transmissions, links it to the introduction of risperidone J-3, and alerts the coordinating doctor. He stops the risperidone, prescribes a neuropsychological reevaluation, and initiates a non-pharmacological management of agitation (environmental adaptation, therapeutic bath, music therapy).<\/pee>\n<div class=\"case-study-result\">\n    <pee>&#x2705; <strong>Result&nbsp;:<\/strong> In 5 days, Mrs. Petit returns to her baseline level. The neuropsychological evaluation reveals cognitive fluctuations and mild visual hallucinations that had not been documented until then. A diagnostic reevaluation towards a mixed MCI is initiated. The vigilance of a caregiver has prevented a potentially irreversible aggravation.<\/pee>\n  <\/div>\n<\/div>\n<div class=\"key-points\">\n<h3>&#x1F6E1;&#xFE0F; Medication safety checklist in Nursing home<\/h3>\n<ul>\n<li>The precise diagnosis of the neurodegenerative pathology (MCI, FTD, PSP\u2026) is mentioned in the file \u2014 not just \u201cdementia\u201d<\/li>\n<li>A \u201ccontraindicated neuroleptics\u201d alert is visible as soon as the computerized file of MCI residents is opened<\/li>\n<li>Each transfer document explicitly mentions critical medication contraindications<\/li>\n<li>The families of MCI residents have received a medication alert card to keep<\/li>\n<li>The entire caregiving team is trained to identify signs of an adverse drug reaction<\/li>\n<li>The transmissions systematically include the date of introduction of any new medication<\/li>\n<li>Any cognitive or behavioral aggravation within 7 days following a treatment modification is reported to the doctor<\/li>\n<li>The coordinating doctor regularly reevaluates the relevance of ongoing neuroleptics<\/li>\n<\/ul>\n<\/div>\n<pee>Medication safety is a collective responsibility that involves doctors, pharmacists, nurses, and caregivers \u2014 and even families. In dementias, where residents often cannot report their adverse effects themselves, this collective responsibility is even more important. Knowing contraindications, observing accurately, transmitting rigorously, and alerting without hesitation: these are the four pillars of a medication safety culture in Nursing homes.<\/pee>\n<div class=\"cta-box\">\n<h3>&#x1F393; Train your team on medication safety in dementias<\/h3>\n<pee>The DYNSEO training on Alzheimer&#8217;s-related diseases includes a comprehensive module on medication contraindications, alert signs, and safety protocols. Qualiopi certified program, suitable for the entire Nursing home team.<\/pee>\n<div class=\"cta-buttons\">\n    <a href=\"https:\/\/www.dynseo.com\/en\/courses\/diseases-related-to-alzheimers-disease-understanding-distinguishing-and-adapting-practices-in-medicalized-residences-en\/\" class=\"btn-cta-white\">&#x1F4CB; View the program<\/a><br \/>\n    <a href=\"https:\/\/www.dynseo.com\/formations\/\" class=\"btn-cta-outline\">All trainings &#x2192;<\/a>\n  <\/div>\n<\/div>\n<div class=\"article-tags\">\n  <a href=\"#\" class=\"article-tag\">neuroleptics dementia<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">medication contraindications Nursing home<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">medication safety<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">MCI neuroleptics<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">BPSD dementia<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">non-pharmacological alternatives<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">caregiver training Nursing home<\/a><br \/>\n  <a href=\"#\" class=\"article-tag\">DYNSEO<\/a>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":410101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" admin_label=\"Article HTML\" _builder_version=\"4.16\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_row admin_label=\"Contenu\" _builder_version=\"4.16\" width=\"100%\" max_width=\"100%\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.16\" global_colors_info=\"{}\"][et_pb_code admin_label=\"HTML import\u00e9\" _builder_version=\"4.16\" global_colors_info=\"{}\"]<style type=\"text\/css\">\n:root{\n  --bleu:#5e5ed7;--bleu-soft:#eeeeff;--bleu2:#5268c9;--bleu2-soft:#e8ecfa;\n  --vert:#a9e2e4;--vert-soft:#e4f5f6;--jaune:#ffeca7;--jaune-soft:#fff8e0;\n  --rose:#e73469;--rose-soft:#fde8ef;--dark:#1a1a2e;--radius:20px;\n  --shadow:0 4px 20px rgba(0,0,0,.05);\n}\n.dbi-art-b4c810 * {margin:0;padding:0;box-sizing:border-box;}\n.dbi-art-b4c810 {scroll-behavior:smooth;}\n.dbi-art-b4c810 {font-family:'Poppins',-apple-system,BlinkMacSystemFont,sans-serif;line-height:1.75;color:#333;background:#fff;overflow-x:hidden;}\n.dbi-art-b4c810 img {max-width:100%;height:auto;display:block;}\n.dbi-art-b4c810 a {color:inherit;text-decoration:none;}\n.dbi-art-b4c810 .container {max-width:820px;margin:0 auto;padding:0 24px;}\n.dbi-art-b4c810 .article-hero {background:var(--rose-soft);padding:70px 24px 0;position:relative;overflow:visible;}\n.dbi-art-b4c810 .article-hero-curve {position:absolute;bottom:-2px;left:0;right:0;width:100%;height:60px;background:#fff;border-radius:50% 50% 0 0;z-index:4;}\n.dbi-art-b4c810 .article-hero-inner {max-width:820px;margin:0 auto;position:relative;z-index:3;padding-bottom:80px;}\n.dbi-art-b4c810 .article-breadcrumb {font-size:12px;color:var(--bleu);margin-bottom:20px;}\n.dbi-art-b4c810 .article-breadcrumb a {color:var(--bleu);border-bottom:1px solid rgba(94,94,215,.25);transition:border-color .2s;}\n.dbi-art-b4c810 .article-breadcrumb a:hover {border-bottom-color:var(--bleu);}\n.dbi-art-b4c810 .article-category {display:inline-block;font-family:'Montserrat',sans-serif;font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:var(--rose);background:#fff;border-radius:30px;padding:7px 18px;margin-bottom:16px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .article-hero h1 {font-family:'Montserrat',sans-serif;font-size:clamp(24px,4vw,34px);font-weight:800;color:var(--dark);line-height:1.3;margin-bottom:16px;}\n.dbi-art-b4c810 .article-hero h1 .hl {display:inline;color:#fff;background:var(--rose);border-radius:8px;padding:1px 12px 3px;}\n.dbi-art-b4c810 .article-meta {font-size:13px;color:#555;display:flex;gap:20px;flex-wrap:wrap;align-items:center;}\n.dbi-art-b4c810 .article-meta span {display:flex;align-items:center;gap:6px;}\n.dbi-art-b4c810 .article-body {padding:50px 0 60px;}\n.dbi-art-b4c810 .article-body p {margin-bottom:20px;text-align:justify;font-size:15px;color:#444;line-height:1.85;}\n.dbi-art-b4c810 .article-body strong {color:var(--dark);font-weight:600;}\n.dbi-art-b4c810 .article-body h2 {font-family:'Montserrat',sans-serif;font-size:clamp(20px,3vw,26px);font-weight:800;color:var(--dark);margin:50px 0 18px;line-height:1.3;padding-bottom:10px;border-bottom:3px solid var(--vert);}\n.dbi-art-b4c810 .article-body h3 {font-family:'Montserrat',sans-serif;font-size:clamp(17px,2.5vw,20px);font-weight:700;color:var(--bleu);margin:35px 0 14px;line-height:1.35;}\n.dbi-art-b4c810 .key-points {background:var(--vert-soft);padding:30px 32px;border-radius:var(--radius);margin:35px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .key-points h3 {font-family:'Montserrat',sans-serif;font-size:17px;font-weight:800;color:var(--bleu2);margin:0 0 14px;}\n.dbi-art-b4c810 .key-points ul {list-style:none;padding:0;margin:0;}\n.dbi-art-b4c810 .key-points li {margin:10px 0;padding-left:26px;position:relative;color:#444;font-size:14px;line-height:1.7;}\n.dbi-art-b4c810 .key-points li::before {content:'2713';position:absolute;left:0;color:var(--bleu);font-weight:800;}\n.dbi-art-b4c810 .info-box {background:var(--bleu-soft);padding:28px 30px;border-radius:var(--radius);margin:35px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .info-box p {font-size:14px;color:#444;margin-bottom:10px;}\n.dbi-art-b4c810 .info-box p:last-child {margin-bottom:0;}\n.dbi-art-b4c810 .info-box strong {color:var(--dark);}\n.dbi-art-b4c810 .article-quote {background:var(--jaune-soft);padding:32px 30px;border-radius:var(--radius);margin:40px 0;box-shadow:var(--shadow);position:relative;}\n.dbi-art-b4c810 .article-quote::before {content:'201C';font-size:100px;position:absolute;top:-20px;left:20px;font-family:Georgia,serif;color:var(--jaune);opacity:.5;}\n.dbi-art-b4c810 .article-quote p {font-size:14px;font-style:italic;color:#444;position:relative;z-index:1;margin-bottom:10px;text-align:left;}\n.dbi-art-b4c810 .article-quote .quote-author {font-family:'Montserrat',sans-serif;font-weight:800;font-style:normal;color:var(--bleu);font-size:13px;}\n.dbi-art-b4c810 .numbered-list {counter-reset:steps;margin:25px 0;padding:0;list-style:none;}\n.dbi-art-b4c810 .numbered-list li {counter-increment:steps;margin:16px 0;padding:18px 22px 18px 70px;border-radius:var(--radius);box-shadow:var(--shadow);position:relative;font-size:14px;color:#444;line-height:1.7;}\n.dbi-art-b4c810 .numbered-list li:nth-child(1) {background:var(--vert-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(2) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(3) {background:var(--jaune-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(4) {background:var(--rose-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(5) {background:var(--bleu2-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(6) {background:var(--vert-soft);}\n.dbi-art-b4c810 .numbered-list li:nth-child(7) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .numbered-list li::before {content:counter(steps);position:absolute;left:18px;top:50%;transform:translateY(-50%);width:38px;height:38px;border-radius:12px;background:rgba(255,255,255,.85);font-family:'Montserrat',sans-serif;font-weight:800;font-size:16px;display:flex;align-items:center;justify-content:center;color:var(--bleu);}\n.dbi-art-b4c810 .numbered-list li strong {color:var(--dark);}\n.dbi-art-b4c810 .comparison-table {width:100%;border-collapse:separate;border-spacing:0;border-radius:var(--radius);overflow:hidden;box-shadow:var(--shadow);margin:30px 0;}\n.dbi-art-b4c810 .comparison-table thead th {background:var(--bleu);color:#fff;font-family:'Montserrat',sans-serif;font-size:13px;font-weight:700;padding:16px 18px;text-align:left;}\n.dbi-art-b4c810 .comparison-table tbody td {padding:14px 18px;font-size:13px;color:#444;vertical-align:top;}\n.dbi-art-b4c810 .comparison-table tbody tr:nth-child(odd) {background:var(--bleu-soft);}\n.dbi-art-b4c810 .comparison-table tbody tr:nth-child(even) {background:var(--vert-soft);}\n.dbi-art-b4c810 .comparison-table tbody td:first-child {font-weight:600;color:var(--dark);}\n.dbi-art-b4c810 .danger-table thead th {background:var(--rose);}\n.dbi-art-b4c810 .case-study {background:#fff;padding:30px 32px;border-radius:var(--radius);margin:30px 0;box-shadow:0 6px 25px rgba(0,0,0,.07);}\n.dbi-art-b4c810 .case-study-header {display:flex;align-items:center;gap:14px;margin-bottom:16px;}\n.dbi-art-b4c810 .case-study-emoji {font-size:2.2rem;}\n.dbi-art-b4c810 .case-study-label {font-family:'Montserrat',sans-serif;font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;margin-bottom:2px;}\n.dbi-art-b4c810 .case-study-title {font-family:'Montserrat',sans-serif;font-size:17px;font-weight:800;color:var(--dark);}\n.dbi-art-b4c810 .case-study p {font-size:14px;color:#444;line-height:1.75;margin-bottom:12px;}\n.dbi-art-b4c810 .case-study p:last-child {margin-bottom:0;}\n.dbi-art-b4c810 .case-study-result {background:var(--vert-soft);padding:16px 20px;border-radius:14px;margin-top:16px;}\n.dbi-art-b4c810 .case-study-result p {margin:0;font-size:13px;color:var(--dark);}\n.dbi-art-b4c810 .case-study:nth-child(odd) .case-study-label {color:var(--bleu);}\n.dbi-art-b4c810 .case-study:nth-child(even) .case-study-label {color:var(--rose);}\n.dbi-art-b4c810 .case-study:nth-child(even) .case-study-result {background:var(--bleu-soft);}\n.dbi-art-b4c810 .error-box {background:var(--rose-soft);padding:24px 28px;border-radius:var(--radius);margin:20px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .error-box-title {font-family:'Montserrat',sans-serif;font-size:15px;font-weight:800;color:var(--rose);margin-bottom:8px;}\n.dbi-art-b4c810 .error-box p {font-size:14px;color:#444;margin:0;line-height:1.7;}\n.dbi-art-b4c810 .error-fix {background:var(--vert-soft);padding:24px 28px;border-radius:var(--radius);margin:8px 0 30px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .error-fix-title {font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;color:var(--bleu);margin-bottom:6px;}\n.dbi-art-b4c810 .error-fix p {font-size:14px;color:#444;margin:0;line-height:1.7;}\n.dbi-art-b4c810 .cta-box {background:linear-gradient(135deg,var(--bleu) 0%,var(--bleu2) 100%);padding:40px 36px;border-radius:22px;margin:50px 0;text-align:center;color:#fff;}\n.dbi-art-b4c810 .cta-box h3 {font-family:'Montserrat',sans-serif;font-size:22px;font-weight:800;margin-bottom:12px;}\n.dbi-art-b4c810 .cta-box p {font-size:14px;color:rgba(255,255,255,.85);margin-bottom:24px;max-width:550px;margin-left:auto;margin-right:auto;}\n.dbi-art-b4c810 .cta-box .cta-buttons {display:flex;justify-content:center;gap:14px;flex-wrap:wrap;}\n.dbi-art-b4c810 .btn-cta-white {display:inline-block;padding:14px 34px;border-radius:30px;font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;background:#fff;color:var(--bleu);transition:all .3s ease;}\n.dbi-art-b4c810 .btn-cta-white:hover {background:var(--rose);color:#fff;transform:translateY(-2px);}\n.dbi-art-b4c810 .btn-cta-outline {display:inline-block;padding:14px 34px;border-radius:30px;font-family:'Montserrat',sans-serif;font-size:14px;font-weight:700;border:2px solid rgba(255,255,255,.5);color:#fff;transition:all .3s ease;}\n.dbi-art-b4c810 .btn-cta-outline:hover {border-color:#fff;background:rgba(255,255,255,.1);}\n.dbi-art-b4c810 .internal-link {display:flex;align-items:center;gap:20px;background:var(--jaune-soft);padding:24px 28px;border-radius:var(--radius);box-shadow:var(--shadow);margin:40px 0;transition:all .3s ease;}\n.dbi-art-b4c810 .internal-link:hover {transform:translateY(-3px);box-shadow:0 8px 28px rgba(0,0,0,.1);}\n.dbi-art-b4c810 .internal-link-icon {font-size:2.5rem;flex-shrink:0;}\n.dbi-art-b4c810 .internal-link-content {flex:1;min-width:0;}\n.dbi-art-b4c810 .internal-link-label {font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:var(--rose);margin-bottom:4px;}\n.dbi-art-b4c810 .internal-link-title {font-family:'Montserrat',sans-serif;font-size:16px;font-weight:800;color:var(--dark);margin-bottom:4px;}\n.dbi-art-b4c810 .internal-link-desc {font-size:13px;color:#555;}\n.dbi-art-b4c810 .internal-link-arrow {font-size:1.5rem;color:var(--bleu);flex-shrink:0;transition:transform .3s;}\n.dbi-art-b4c810 .internal-link:hover .internal-link-arrow {transform:translateX(4px);}\n.dbi-art-b4c810 .article-tags {display:flex;flex-wrap:wrap;gap:8px;margin:40px 0 20px;padding-top:30px;border-top:2px solid #f0f0f0;}\n.dbi-art-b4c810 .article-tag {display:inline-block;padding:6px 16px;border-radius:30px;font-size:12px;font-weight:600;transition:all .2s;}\n.dbi-art-b4c810 .article-tag:nth-child(odd) {color:var(--bleu);background:var(--bleu-soft);}\n.dbi-art-b4c810 .article-tag:nth-child(even) {color:var(--rose);background:var(--rose-soft);}\n.dbi-art-b4c810 .article-tag:hover {transform:translateY(-2px);box-shadow:0 3px 10px rgba(0,0,0,.08);}\n.dbi-art-b4c810 .toc {background:var(--bleu2-soft);padding:28px 30px;border-radius:var(--radius);margin:0 0 40px;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .toc h4 {font-family:'Montserrat',sans-serif;font-size:14px;font-weight:800;color:var(--dark);margin-bottom:14px;}\n.dbi-art-b4c810 .toc ol {padding-left:20px;margin:0;}\n.dbi-art-b4c810 .toc li {margin:8px 0;font-size:13px;}\n.dbi-art-b4c810 .toc a {color:var(--bleu);font-weight:600;border-bottom:1px solid transparent;transition:border-color .2s;}\n.dbi-art-b4c810 .toc a:hover {border-bottom-color:var(--bleu);}\n.dbi-art-b4c810 .alerte-box {background:#fff0f0;border-left:5px solid var(--rose);padding:24px 28px;border-radius:0 var(--radius) var(--radius) 0;margin:30px 0;box-shadow:var(--shadow);}\n.dbi-art-b4c810 .alerte-box-title {font-family:'Montserrat',sans-serif;font-size:16px;font-weight:800;color:var(--rose);margin-bottom:10px;}\n.dbi-art-b4c810 .alerte-box p {font-size:14px;color:#444;margin:0;line-height:1.75;}\n@media(max-width:600px) {\n.dbi-art-b4c810 .article-hero {padding:50px 16px 0;}\n.dbi-art-b4c810 .article-hero-curve {height:40px;}\n.dbi-art-b4c810 .article-hero-inner {padding-bottom:60px;}\n.dbi-art-b4c810 .article-meta {flex-direction:column;gap:8px;}\n.dbi-art-b4c810 .container {padding:0 16px;}\n.dbi-art-b4c810 .article-body p {font-size:14px;}\n.dbi-art-b4c810 .key-points, .dbi-art-b4c810 .info-box, .dbi-art-b4c810 .error-box, .dbi-art-b4c810 .error-fix {padding:24px 20px;}\n.dbi-art-b4c810 .article-quote {padding:24px 20px;}\n.dbi-art-b4c810 .case-study {padding:24px 20px;}\n.dbi-art-b4c810 .numbered-list li {padding:16px 16px 16px 60px;}\n.dbi-art-b4c810 .cta-box {padding:30px 20px;}\n.dbi-art-b4c810 .cta-box h3 {font-size:19px;}\n.dbi-art-b4c810 .cta-box .cta-buttons {flex-direction:column;max-width:260px;margin-left:auto;margin-right:auto;}\n.dbi-art-b4c810 .btn-cta-white, .dbi-art-b4c810 .btn-cta-outline {width:100%;text-align:center;padding:13px 24px;font-size:13px;}\n.dbi-art-b4c810 .internal-link {flex-direction:column;text-align:center;gap:12px;padding:22px 18px;}\n.dbi-art-b4c810 .internal-link-arrow {transform:rotate(90deg);}\n.dbi-art-b4c810 .internal-link:hover .internal-link-arrow {transform:rotate(90deg) translateX(4px);}\n.dbi-art-b4c810 .comparison-table {font-size:12px;}\n.dbi-art-b4c810 .comparison-table thead th, .dbi-art-b4c810 .comparison-table tbody td {padding:10px 12px;}\n.dbi-art-b4c810 .toc {padding:22px 20px;}\n}\n\n<\/style>\n<script type=\"application\/ld+json\">\n{\n  \"@context\":\"https:\/\/schema.org\",\n  \"@type\":\"Article\",\n  \"headline\":\"Neuroleptiques et d\u00e9mence : les contre-indications que tout soignant doit conna\u00eetre\",\n  \"description\":\"Guide complet sur les risques des neuroleptiques dans les d\u00e9mences en EHPAD : contre-indications absolues (DCL), alternatives non m\u00e9dicamenteuses, protocoles de s\u00e9curit\u00e9 au transfert.\",\n  \"author\":{\"@type\":\"Organization\",\"name\":\"DYNSEO\",\"url\":\"https:\/\/www.dynseo.com\"},\n  \"publisher\":{\"@type\":\"Organization\",\"name\":\"DYNSEO\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/www.dynseo.com\/wp-content\/uploads\/2021\/03\/logo-dynseo.png\"}},\n  \"datePublished\":\"2026-03-06\",\n  \"dateModified\":\"2026-03-06\",\n  \"mainEntityOfPage\":\"https:\/\/www.dynseo.com\/neuroleptiques-demence-contre-indications-ehpad\/\"\n}\n<\/script>\n<div class=\"dbi-art-b4c810\">\n<header class=\"article-hero\">\n  <div class=\"article-hero-inner\">\n    <nav class=\"article-breadcrumb\">\n      <a href=\"https:\/\/www.dynseo.com\/\">Home<\/a> &rsaquo;\n      <a href=\"https:\/\/www.dynseo.com\/professionnels-de-sante\/\">Professionals<\/a> &rsaquo;\n      Neuroleptics and dementia in Nursing home\n    <\/nav>\n    <span class=\"article-category\">&#x26A0;&#xFE0F; MEDICATION SAFETY<\/span>\n    <h1>Neuroleptics and dementia&nbsp;: the <span class=\"hl\">absolute contraindications<\/span> that every caregiver must know<\/h1>\n    <div class=\"article-meta\">\n      <span>&#x1F4C5; March 2026<\/span>\n      <span>&#x23F1; 17 min read<\/span>\n      <span>&#x1F9D1;&#x200D;&#x2695;&#xFE0F; By the DYNSEO team<\/span>\n    <\/div>\n  <\/div>\n  <div class=\"article-hero-curve\"><\/div>\n<\/header>\n\n<div class=\"container\">\n<article class=\"article-body\">\n\n<div class=\"toc\">\n  <h4>&#x1F4D1; Table of contents<\/h4>\n  <ol>\n    <li><a href=\"#pourquoi\">Why neuroleptics are so often prescribed in Nursing home<\/a><\/li>\n    <li><a href=\"#mecanisme\">How neuroleptics act on the demented brain<\/a><\/li>\n    <li><a href=\"#dcl-danger\">DCL: the absolute and potentially fatal contraindication<\/a><\/li>\n    <li><a href=\"#alzheimer\">Alzheimer's disease and neuroleptics: underestimated risks<\/a><\/li>\n    <li><a href=\"#dft\">DFT and other dementias: what the literature says<\/a><\/li>\n    <li><a href=\"#autres-molecules\">Other risky molecules in dementias<\/a><\/li>\n    <li><a href=\"#alternatives\">Non-drug alternatives to neuroleptics<\/a><\/li>\n    <li><a href=\"#protocole-transfert\">Securing transfers: the medication liaison sheet<\/a><\/li>\n    <li><a href=\"#role-soignant\">The caregiver's role in medication vigilance<\/a><\/li>\n    <li><a href=\"#cas-pratiques\">Practical cases: spotting and alerting<\/a><\/li>\n  <\/ol>\n<\/div>\n\n<p>In France, neuroleptics are among the most frequently prescribed medications for elderly people living in Nursing home. According to data from the Haute Autorit\u00e9 de Sant\u00e9, more than 20&nbsp;% of demented residents receive an antipsychotic, while official recommendations limit their use to very specific and short-term situations. This gap between recommendations and practices has real consequences on the health, quality of life, and safety of residents.<\/p>\n\n<p>For the majority of dementias, neuroleptics present serious side effects \u2014 falls, confusion, excessive sedation, acceleration of cognitive decline. In Lewy body dementia, they can be <strong>directly fatal<\/strong>. In frontotemporal dementia, they are often ineffective on target behaviors while adding metabolic and neurological risks.<\/p>\n\n<p>This guide is aimed at all professionals involved in the medication circuit in Nursing home \u2014 nurses, nursing assistants, coordinating doctors, pharmacists \u2014 with a clear objective&nbsp;: <strong>to know the risks, identify warning signals, and act to secure residents<\/strong>.<\/p>\n\n<div class=\"alerte-box\">\n<div class=\"alerte-box-title\">&#x1F6A8; Important prior warning<\/div>\n  <p>This article is a training and awareness tool. It does not replace the opinion of the prescribing doctor. No decision to stop or modify a treatment should be made without a medical prescription. However, <strong>every caregiving team not only has the right but the duty to alert the coordinating doctor<\/strong> if they observe signs indicative of an adverse reaction to a medication.<\/p>\n<\/div>\n\n<h2 id=\"pourquoi\">1. Why neuroleptics are so often prescribed in Nursing homes<\/h2>\n\n<p>Neuroleptics \u2014 also called antipsychotics \u2014 are medications originally developed to treat schizophrenia and psychoses. Their effectiveness on hallucinations and delusional thoughts in these pathologies has led to their widespread use in behavioral disorders of dementia: agitation, aggression, nighttime wandering, hallucinations.<\/p>\n\n<p>Several factors explain their frequent prescription in Nursing homes. First, the <strong>pressure of disruptive behaviors<\/strong>: the agitation of a resident in a Nursing home not only affects the resident themselves, it disrupts other residents, exhausts the caregiving team, and generates crisis situations that need to be addressed quickly. Neuroleptics offer an immediate response, which non-drug approaches, more effective in the long term, do not always allow.<\/p>\n\n<p>Next, the <strong>lack of training on alternatives<\/strong>: many teams in Nursing homes do not have the necessary tools and protocols to manage behavioral disorders without quickly resorting to medication. Training in behavioral approaches, validation, and environmental adaptation remains insufficient in many facilities.<\/p>\n\n<p>Finally, the <strong>pressure from families<\/strong>: relatives exhausted by their parent's agitation may explicitly request a sedative treatment, putting the doctor in a delicate position. Prescribing a neuroleptic may appear as a response to a legitimate request for relief.<\/p>\n<div class=\"info-box\">\n  <p><strong>&#x1F4CA; What the data says.<\/strong> The HAS reminds in its recommendations that neuroleptics are indicated in BPSD (Behavioral and Psychological Symptoms of Dementia) only as a second-line treatment, after failure of non-drug approaches, in cases of severe symptoms presenting a risk to the resident or their surroundings, for the shortest duration possible (a few weeks), with regular reevaluation. In practice, these conditions are not always respected: treatments initially prescribed for an acute crisis sometimes persist for months or years without reevaluation.<\/p>\n<\/div>\n\n<h2 id=\"mecanisme\">2. How neuroleptics act on the demented brain<\/h2>\n\n<p>Neuroleptics primarily act by blocking D2 dopamine receptors in the brain. This blockage reduces dopaminergic activity in the mesolimbic circuits, which explains their antipsychotic effect. However, this same blockage in other brain circuits generates unwanted effects: blockage of dopamine receptors in the nigrostriatal pathways (extrapyramidal syndrome), in the hypothalamus (metabolic and hormonal disturbances), and in other neurotransmission systems (antihistaminic, anticholinergic, antiadrenergic).<\/p>\n\n<p>In elderly demented individuals, these unwanted effects are amplified for several reasons. Aging reduces brain reserve and the ability to adapt to neurochemical disturbances. Frequent polypharmacy in the elderly multiplies interactions. And certain neurodegenerative pathologies \u2014 particularly MCI \u2014 create a specific vulnerability to dopaminergic molecules.<\/p>\n\n<h3>Common unwanted effects in all dementias<\/h3>\n\n<p>Even in the most legitimate indications, neuroleptics in demented individuals expose them to a range of documented unwanted effects: <strong>excessive sedation<\/strong> that worsens cognitive and functional deficits, <strong>extrapyramidal syndrome<\/strong> (rigidity, bradykinesia, gait disturbances, increased risk of falls), <strong>orthostatic hypotension<\/strong> (dizziness upon standing, falls), <strong>prolongation of the QT interval<\/strong> (risk of cardiac arrhythmia), <strong>anticholinergic effects<\/strong> (dry mouth, constipation, urinary retention, worsened confusion), and <strong>metabolic syndrome<\/strong> (weight gain, diabetes).<\/p>\n\n<p>A meta-analysis published in the <em>British Medical Journal<\/em> confirmed that antipsychotics increase the risk of mortality in elderly demented individuals, regardless of the underlying pathology. This risk is approximately 1.5 to 1.7 times that observed without antipsychotics. It is based on this data that European and American regulatory agencies have issued official warnings regarding the use of antipsychotics in dementias.<\/p>\n\n<h2 id=\"dcl-danger\">3. MCI: the absolute and potentially fatal contraindication<\/h2>\n\n<p>Lewy body dementia represents the most critical case in terms of medication safety. Sensitivity to neuroleptics in MCI is not just another unwanted effect on a long list: it is an <strong>unpredictable, rapid, and potentially fatal<\/strong> reaction that occurs in 30 to 50% of exposed patients.<\/p>\n\n<h3>The hypersensitivity syndrome to neuroleptics in MCI<\/h3>\n\n<p>This syndrome typically manifests within hours or days following the introduction of the neuroleptic. It is characterized by a <strong>brutal and severe worsening of confusion<\/strong> (the resident who was partially autonomous becomes completely disoriented), <strong>intense muscle rigidity<\/strong> sometimes accompanied by abnormal postures, <strong>hyperthermia<\/strong>, <strong>blood pressure instability<\/strong>, and consciousness disturbances that can lead to coma. Without rapid medical intervention, this condition can be fatal.<\/p>\n\n<p>The mechanism is related to the dopaminergic deficiency specific to MCI. The dopaminergic neurons in the substantia nigra are already severely affected by Lewy bodies. Blocking the residual dopamine receptors with a neuroleptic amounts to cutting off the little dopaminergic signal still available in these circuits, leading to a sudden neurological collapse.<\/p>\n\n<h3>All neuroleptics are concerned<\/h3>\n\n<p>A common mistake is to believe that only \"typical\" neuroleptics (haloperidol, chlorpromazine) are dangerous in MCI and that \"atypical\" neuroleptics (risperidone, olanzapine) are safe. This distinction is <strong>false and dangerous<\/strong>: atypical neuroleptics present the same risk of hypersensitivity in MCI, even if their overall profile of unwanted effects differs. Risperidone and olanzapine in particular have been associated with severe reactions in MCI.<\/p>\n\n<p>Quetiapine (Seroquel) is sometimes mentioned as being better tolerated in MCI, due to its different receptor binding profile. It may be used in certain cases by specialized teams, at very low doses and with close monitoring. However, it can in no way be considered \"risk-free\" in MCI and must always be subject to a specialized medical decision.<\/p>\n<div class=\"alerte-box\">\n  <div class=\"alerte-box-title\">&#x1F6A8; Absolute contraindication \u2014 to memorize and to transmit<\/div>\n  <p>Classic neuroleptics and the majority of atypical neuroleptics are <strong>formally contraindicated<\/strong> in Lewy body dementia. This contraindication must be clearly stated in the care file, in any transfer document, and in the resident's health booklet. It must be known by the entire care team, by the family, and by any physician involved with the resident.<\/p>\n<\/div>\n\n<table class=\"comparison-table danger-table\">\n  <thead>\n    <tr>\n      <th>Molecule<\/th>\n      <th>Brand name<\/th>\n      <th>DCL Risk<\/th>\n      <th>Status<\/th>\n    <\/tr>\n  <\/thead>\n  <tbody>\n    <tr>\n      <td>Haloperidol<\/td>\n      <td>Haldol<\/td>\n      <td>Severe hypersensitivity syndrome, mortality<\/td>\n      <td>CONTRAINDICATED<\/td>\n    <\/tr>\n    <tr>\n      <td>Chlorpromazine<\/td>\n      <td>Largactil<\/td>\n      <td>Hypersensitivity syndrome, major extrapyramidal effects<\/td>\n      <td>CONTRAINDICATED<\/td>\n    <\/tr>\n    <tr>\n      <td>Tiapride<\/td>\n      <td>Tiapridal<\/td>\n      <td>Severe extrapyramidal syndrome, cognitive worsening<\/td>\n      <td>CONTRAINDICATED<\/td>\n    <\/tr>\n    <tr>\n      <td>Risperidone<\/td>\n      <td>Risperdal<\/td>\n      <td>Hypersensitivity, Stroke, increased mortality<\/td>\n      <td>CONTRAINDICATED<\/td>\n    <\/tr>\n    <tr>\n      <td>Olanzapine<\/td>\n      <td>Zyprexa<\/td>\n      <td>Hypersensitivity, deep sedation, mortality<\/td>\n      <td>TO AVOID<\/td>\n    <\/tr>\n    <tr>\n      <td>Quetiapine<\/td>\n      <td>Seroquel<\/td>\n      <td>Lower but real risk \u2014 specialized use only<\/td>\n      <td>SPECIALIZED ADVICE REQUIRED<\/td>\n    <\/tr>\n    <tr>\n      <td>Aripiprazole<\/td>\n      <td>Abilify<\/td>\n      <td>Insufficient data in DCL \u2014 to avoid as a precaution<\/td>\n      <td>TO AVOID<\/td>\n    <\/tr>\n  <\/tbody>\n<\/table>\n\n<h2 id=\"alzheimer\">4. Alzheimer's disease and neuroleptics: underestimated risks<\/h2>\n\n<p>In Alzheimer's disease, neuroleptics are not absolutely contraindicated as in DCL, but they still present a significant risk profile that justifies reserving them for the most severe situations, as a last resort, and for short durations.<\/p>\n\n<h3>Modest efficacy on target symptoms<\/h3>\n\n<p>Clinical studies on antipsychotics in Alzheimer's BPSD show modest efficacy, primarily limited to severe aggression and psychotic symptoms (hallucinations, delusions). They have no demonstrated efficacy on wandering, pacing, apathy, or sleep disorders \u2014 yet these are among the most frequent reasons for prescription in real practice. The use of neuroleptics for these symptoms is therefore both risky and poorly supported by evidence.<\/p>\n\n<h3>Acceleration of cognitive decline<\/h3>\n\n<p>Several longitudinal studies have shown that prolonged use of antipsychotics in Alzheimer's disease is associated with an <strong>acceleration of cognitive decline<\/strong> compared to untreated residents. This effect adds to the natural progression of the disease and reduces the window of functional and relational abilities of the resident. For families seeking to maintain contact and communication with their loved one, this effect has concrete consequences on the quality of visits.<\/p>\n\n<h3>The risk of Stroke<\/h3>\n\n<p>Atypical antipsychotics (risperidone, olanzapine, aripiprazole) have been the subject of regulatory alerts due to an <strong>increased risk of Stroke<\/strong> in elderly demented individuals. This risk, documented in controlled clinical trials, has led to an official warning against their off-label use in dementias. Risperidone is the only antipsychotic with marketing authorization for BPSD in Europe, under very strict conditions and for a maximum duration of 6 weeks.<\/p>\n\n<h2 id=\"dft\">5. DFT and other dementias: what the literature says<\/h2>\n\n<p>In frontotemporal dementia, neuroleptics are often prescribed to manage disinhibition and agitation. Their efficacy on these frontal behaviors is, however, very limited, or even null, for a simple neurobiological reason: the disinhibited behaviors of DFT are not mediated by the mesolimbic dopaminergic circuits on which antipsychotics act, but by the degeneration of fronto-striatal serotonergic and glutamatergic circuits.<\/p>\n\n<p>Serotonin reuptake inhibitors (SRIs, such as sertraline or fluoxetine) have shown modest but real efficacy on disinhibition and hyperphagia in DFTvc, with a side effect profile much more favorable than antipsychotics. They represent a medication alternative to be evaluated with the coordinating physician before resorting to neuroleptics.<\/p>\n\n<p>In vascular dementia, neuroleptics present the same general risks as in Alzheimer's, with an additionally potentially increased cardiovascular risk due to the vascular comorbidities usually associated. In PSP, the profile of subcortical dopaminergic denervation is similar to that of DCL, which justifies great caution regarding neuroleptics in this pathology as well.<\/p>\n\n<h2 id=\"autres-molecules\">6. Other risky molecules in dementias<\/h2>\n\n<p>Neuroleptics are not the only molecules to monitor in dementias. Many commonly used medications in geriatrics present problematic side effect profiles in individuals already weakened by a neurodegenerative condition.<\/p>\n\n<table class=\"comparison-table\">\n  <thead>\n    <tr>\n      <th>Drug class<\/th>\n      <th>Common medications<\/th>\n      <th>Main risk in dementias<\/th>\n      <th>Particular vigilance<\/th>\n    <\/tr>\n  <\/thead>\n  <tbody>\n    <tr>\n      <td>Urinary anticholinergics<\/td>\n      <td>Oxybutynin (Ditropan), solifenacin (V\u00e9sicare)<\/td>\n      <td>Worsening confusion, hallucinations, memory disorders<\/td>\n      <td>DCL, Alzheimer's<\/td>\n    <\/tr>\n    <tr>\n      <td>Sedative antihistamines<\/td>\n      <td>Hydroxyzine (Atarax), diphenhydramine<\/td>\n      <td>Anticholinergic effects, sedation, confusion<\/td>\n      <td>All dementias<\/td>\n    <\/tr>\n    <tr>\n      <td>Benzodiazepines<\/td>\n      <td>Diazepam, lorazepam, alprazolam, zolpidem<\/td>\n      <td>Falls, excessive sedation, worsening fluctuations (DCL)<\/td>\n      <td>Particularly DCL<\/td>\n    <\/tr>\n    <tr>\n      <td>Tricyclic antidepressants<\/td>\n      <td>Amitriptyline (Laroxyl), clomipramine<\/td>\n      <td>Anticholinergic effects, confusion, cardiotoxicity<\/td>\n      <td>DCL, frail elderly people<\/td>\n    <\/tr>\n    <tr>\n      <td>Antispasmodics<\/td>\n      <td>Tiemonium (Visc\u00e9ralgine), scopolamine<\/td>\n      <td>Anticholinergic effects, acute confusion<\/td>\n      <td>All dementias<\/td>\n    <\/tr>\n    <tr>\n      <td>Corticosteroids<\/td>\n      <td>Prednisone, methylprednisolone<\/td>\n      <td>Acute confusion, corticosteroid-induced psychosis, agitation<\/td>\n      <td>Especially if prolonged treatment<\/td>\n    <\/tr>\n    <tr>\n      <td>Opioids<\/td>\n      <td>Morphine, tramadol, codeine<\/td>\n      <td>Confusion, hallucinations, sedation, falls<\/td>\n      <td>Necessary but to be dosed carefully<\/td>\n    <\/tr>\n  <\/tbody>\n<\/table>\n<div class=\"info-box\">\n  <p><strong>&#x1F4A1; The total anticholinergic score.<\/strong> Many residents with dementia are exposed to multiple medications with moderate anticholinergic effects. The effect of these molecules is cumulative: a high anticholinergic score (sum of the burdens of each medication) is associated with a significantly increased risk of confusion, cognitive decline, and falls. Tools like the Anticholinergic Cognitive Burden (ACB) scale allow doctors and pharmacists to assess this overall risk. In units where this score is calculated regularly, a reduction in hospitalizations for acute confusion is observed.<\/p>\n<\/div>\n\n<h2 id=\"alternatives\">7. Non-pharmacological alternatives to neuroleptics<\/h2>\n\n<p>The best response to behavioral disorders in dementia is non-pharmacological. This is the main conclusion of all good practice recommendations, both French and international. Non-pharmacological approaches have shown equivalent or superior efficacy to neuroleptics on BPSD, with an infinitely more favorable risk profile.<\/p>\n\n<h3>Functional analysis of behavior<\/h3>\n\n<p>Before addressing a disruptive behavior, it is essential to understand it first. Functional analysis involves identifying the <strong>antecedents, the behavior itself, and its consequences<\/strong> (ABC method \u2014 Antecedents, Behavior, Consequences). Often, a behavior of agitation is a response to an unmet need: unexpressed pain, physical discomfort (cold, hunger, need to urinate), overly stimulating environment, feeling of insecurity. Addressing the underlying need is more effective than sedating the reaction.<\/p>\n\n<ol class=\"numbered-list\">\n  <li><strong>Adapting the sensory environment<\/strong> &mdash; reducing noise, visual agitation, adjusting lighting, providing secure walking spaces. A calm and predictable environment significantly reduces agitation in all types of dementia.<\/li>\n  <li><strong>Music therapy<\/strong> &mdash; listening to familiar and appreciated music reduces agitation, anxiety, and disruptive behaviors, with strong evidence in Alzheimer's. Active music (percussion, singing) is particularly effective in frontotemporal dementia and mild cognitive impairment.<\/li>\n  <li><strong>Adapted physical activity<\/strong> &mdash; regular walking, gentle exercises, tai chi reduce agitation and improve sleep quality. Physical activity also has a positive effect on cognitive decline.<\/li>\n  <li><strong>Sensory approaches<\/strong> &mdash; hand massage, aromatherapy, Snoezelen, warm baths. These approaches mobilize non-cognitive sensory pathways that remain accessible even in advanced stages of dementia.<\/li>\n  <li><strong>Validation and appropriate communication<\/strong> &mdash; responding to emotions rather than content, not confronting reality, maintaining a calm and caring presence. These techniques sustainably reduce anxiety and agitation when practiced consistently by the entire team.<\/li>\n  <li><strong>Adapted cognitive stimulation<\/strong> &mdash; offering activities related to residual capacities maintains engagement and reduces wandering or agitation behaviors related to boredom and lack of stimulation.<\/li>\n  <li><strong>Pain management<\/strong> &mdash; untreated pain is one of the leading causes of agitation in advanced dementia. Using pain assessment tools suitable for non-communicative individuals (Doloplus, ECPA) and effectively treating pain often reduces disruptive behaviors without resorting to neuroleptics.<\/li>\n<\/ol>\n\n<a href=\"https:\/\/www.dynseo.com\/courses\/maladies-apparentees-a-la-maladie-dalzheimer-comprendre-distinguer-et-adapter-ses-pratiques\/\" class=\"internal-link\">\n<div class=\"internal-link-icon\">&#x1F393;<\/div>\n  <div class=\"internal-link-content\">\n    <div class=\"internal-link-label\">Certified training<\/div>\n    <div class=\"internal-link-title\">Diseases related to Alzheimer's: understanding, distinguishing, and adapting practices<\/div>\n    <div class=\"internal-link-desc\">DYNSEO Qualiopi training \u2014 medication safety, contraindications, non-drug approaches. Clinical cases for Nursing home teams.<\/div>\n  <\/div>\n  <div class=\"internal-link-arrow\">&#x2192;<\/div>\n<\/a>\n\n<h2 id=\"protocole-transfert\">8. Securing transfers: the medication liaison form<\/h2>\n\n<p>The riskiest moment for a demented resident in terms of medication safety is the <strong>transfer to another facility<\/strong>: emergency room, short hospitalization, specialized consultation, respite stay. In these contexts, the professionals taking care of the resident do not know their file and may prescribe contraindicated molecules due to lack of available information.<\/p>\n\n<h3>Essential elements of the liaison form<\/h3>\n\n<p>Each transfer of a demented resident must be accompanied by a standardized medication liaison form containing at least: the precise diagnosis of the neurodegenerative pathology (specifying whether it is DCL, DFT, PSP, or other \u2014 not just \"dementia\"); the list of ongoing treatments with dosages; the list of contraindicated or at-risk medications with the resident's pathology; allergies and history of medication reactions; and the name and number of the coordinating physician who can be contacted in case of questions.<\/p>\n\n<p>For residents with DCL in particular, this form must include a mention in red and bold characters: <strong>\u201cDEMENTIA WITH LEWY BODIES \u2014 NEUROLEPTICS FORMALLY CONTRAINDICATED \u2014 LIFE-THREATENING RISK\u201d<\/strong>. This mention must be repeated on the discharge prescription, on the accompanying letter, and on the resident's bracelet or medical ID card if the Nursing home uses this type of support.<\/p>\n\n<h3>Training the family as a safety relay<\/h3>\n\n<p>Families can play a crucial role in medication safety during transfers. An informed and trained relative accompanying the resident to the emergency room can alert the emergency physician about contraindications before any prescription. This training is simple: explain to the family which molecules are dangerous for their loved one, provide them with a summary sheet to keep in their wallet or on their phone, and encourage them to show it to any new doctor.<\/p>\n\n<div class=\"article-quote\">\n  <p>\u201cMy mother was hospitalized urgently on a Sunday evening. I had the Nursing home's form in my bag. When the emergency doctor wanted to give her Haldol to calm her down, I was able to show the form. He changed his protocol. I think it saved her life.\u201d<\/p>\n<div class=\"quote-author\">\u2014 Daughter of a DCL resident, Nursing home Normandy<\/div>\n<\/div>\n\n<h2 id=\"role-soignant\">9. The role of the caregiver in medication vigilance<\/h2>\n\n<p>Medication vigilance does not rely solely on doctors and pharmacists. Caregivers in daily contact with the resident are often the first to observe signs of an adverse reaction to a medication \u2014 and are best positioned to report it quickly.<\/p>\n\n<h3>Warning signs to observe and report<\/h3>\n\n<p>Several situations should lead the caregiver to immediately alert the coordinating nurse or doctor: a sudden worsening of confusion in the days following the introduction or increase of a medication, new muscle rigidity or a change in gait, hyperthermia without identified infection, excessive sedation making the resident difficult to wake, newly appeared repeated falls, or new hallucinations in a resident who did not previously exhibit them.<\/p>\n\n<p>Each of these signs, taken in isolation, can have multiple causes. But their <strong>appearance in the days or weeks following the introduction of a new medication<\/strong> should systematically lead to considering a medication reaction and alerting the prescriber. Mentioning the chronology (introduction of the medication D-3, appearance of the sign D0) is valuable clinical information.<\/p>\n\n<h3>Transmission, an essential link<\/h3>\n\n<p>An observation is only valuable if it is transmitted. The monitoring notebook, targeted transmissions, and the synthesis meeting are the channels through which caregivers' observations become actionable medical data. Training caregivers to accurately describe changes in behavior or general condition \u2014 with the time, context, and words of the resident \u2014 significantly improves the quality of collective medication monitoring.<\/p>\n\n<h2 id=\"cas-pratiques\">10. Practical cases: spotting and alerting<\/h2>\n\n<div class=\"case-study\">\n  <div class=\"case-study-header\">\n    <div class=\"case-study-emoji\">&#x1F6A8;<\/div>\n    <div>\n      <div class=\"case-study-label\">Practical case \u2014 Critical reaction DCL<\/div>\n      <div class=\"case-study-title\">Mr. Aubert, 79 years old \u2014 Haldol in the emergency room<\/div>\n    <\/div>\n  <\/div>\n  <p>Mr. Aubert is a resident in a Nursing home with a DCL diagnosis made 6 months earlier. He is transferred to the emergency room on a Saturday night for intense agitation with hallucinations. The emergency doctor, lacking the complete file, prescribes IV haloperidol to calm the agitation. Six hours later, Mr. Aubert presents extreme rigidity, hyperthermia at 39.8\u00b0C, a blood pressure of 80\/50, and is no longer arousable.<\/p>\n  <p>The coordinating doctor, alerted by the night nurse from the Nursing home who had not received any updates, contacts the emergency room and identifies the cause. The transfer liaison form sent during the transfer did mention the DCL but the contraindication to neuroleptics was not highlighted. Mr. Aubert spends 5 days in intensive care before stabilizing.<\/p>\n  <div class=\"case-study-result\">\n    <p>&#x26A0;&#xFE0F; <strong>Lesson:<\/strong> Following this incident, the Nursing home implemented a specific DCL transfer form with a red mention at the top of the document and trained the family to carry a medication alert card. The coordinating doctor also reported the incident to the regional gerontological network to raise awareness among emergency services.<\/p>\n  <\/div>\n<\/div>\n\n<div class=\"case-study\">\n  <div class=\"case-study-header\">\n    <div class=\"case-study-emoji\">&#x1F9D1;&#x200D;&#x2695;&#xFE0F;<\/div>\n    <div>\n      <div class=\"case-study-label\">Practical case \u2014 Caregiver vigilance<\/div>\n<div class=\"case-study-title\">Mrs. Petit, 83 years old \u2014 post-prescription aggravation<\/div>\n    <\/div>\n  <\/div>\n  <p>Mrs. Petit, a resident with a diagnosis of moderate Alzheimer's disease, has been agitated for a few days. The weekend on-call doctor (not the usual coordinating doctor) prescribes risperidone 0.5 mg\/day. Three days later, the morning caregiver notes that Mrs. Petit \u201cis no longer the same\u201d: she remains seated without moving, no longer eats, and does not respond to calls. She notes the observation in the transmissions with the start date.<\/p>\n  <p>The coordinating nurse rereads the transmissions, links it to the introduction of risperidone J-3, and alerts the coordinating doctor. He stops the risperidone, prescribes a neuropsychological reevaluation, and initiates a non-pharmacological management of agitation (environmental adaptation, therapeutic bath, music therapy).<\/p>\n  <div class=\"case-study-result\">\n    <p>&#x2705; <strong>Result&nbsp;:<\/strong> In 5 days, Mrs. Petit returns to her baseline level. The neuropsychological evaluation reveals cognitive fluctuations and mild visual hallucinations that had not been documented until then. A diagnostic reevaluation towards a mixed MCI is initiated. The vigilance of a caregiver has prevented a potentially irreversible aggravation.<\/p>\n  <\/div>\n<\/div>\n\n<div class=\"key-points\">\n  <h3>&#x1F6E1;&#xFE0F; Medication safety checklist in Nursing home<\/h3>\n  <ul>\n    <li>The precise diagnosis of the neurodegenerative pathology (MCI, FTD, PSP\u2026) is mentioned in the file \u2014 not just \u201cdementia\u201d<\/li>\n    <li>A \u201ccontraindicated neuroleptics\u201d alert is visible as soon as the computerized file of MCI residents is opened<\/li>\n    <li>Each transfer document explicitly mentions critical medication contraindications<\/li>\n    <li>The families of MCI residents have received a medication alert card to keep<\/li>\n    <li>The entire caregiving team is trained to identify signs of an adverse drug reaction<\/li>\n    <li>The transmissions systematically include the date of introduction of any new medication<\/li>\n    <li>Any cognitive or behavioral aggravation within 7 days following a treatment modification is reported to the doctor<\/li>\n    <li>The coordinating doctor regularly reevaluates the relevance of ongoing neuroleptics<\/li>\n  <\/ul>\n<\/div>\n\n<p>Medication safety is a collective responsibility that involves doctors, pharmacists, nurses, and caregivers \u2014 and even families. In dementias, where residents often cannot report their adverse effects themselves, this collective responsibility is even more important. Knowing contraindications, observing accurately, transmitting rigorously, and alerting without hesitation: these are the four pillars of a medication safety culture in Nursing homes.<\/p>\n\n<div class=\"cta-box\">\n  <h3>&#x1F393; Train your team on medication safety in dementias<\/h3>\n  <p>The DYNSEO training on Alzheimer's-related diseases includes a comprehensive module on medication contraindications, alert signs, and safety protocols. Qualiopi certified program, suitable for the entire Nursing home team.<\/p>\n  <div class=\"cta-buttons\">\n    <a href=\"https:\/\/www.dynseo.com\/courses\/maladies-apparentees-a-la-maladie-dalzheimer-comprendre-distinguer-et-adapter-ses-pratiques\/\" class=\"btn-cta-white\">&#x1F4CB; View the program<\/a>\n    <a href=\"https:\/\/www.dynseo.com\/formations\/\" class=\"btn-cta-outline\">All trainings &#x2192;<\/a>\n  <\/div>\n<\/div>\n\n<div class=\"article-tags\">\n  <a href=\"#\" class=\"article-tag\">neuroleptics dementia<\/a>\n  <a href=\"#\" class=\"article-tag\">medication contraindications Nursing home<\/a>\n  <a href=\"#\" class=\"article-tag\">medication safety<\/a>\n  <a href=\"#\" class=\"article-tag\">MCI neuroleptics<\/a>\n  <a href=\"#\" class=\"article-tag\">BPSD dementia<\/a>\n  <a href=\"#\" class=\"article-tag\">non-pharmacological alternatives<\/a>\n  <a href=\"#\" class=\"article-tag\">caregiver training Nursing home<\/a>\n  <a href=\"#\" class=\"article-tag\">DYNSEO<\/a>\n<\/div>\n\n<\/article>\n<\/div>\n\n\n<\/div>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","footnotes":""},"categories":[2118],"tags":[],"class_list":["post-708061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/\" \/>\n<meta property=\"og:site_name\" content=\"DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T03:17:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-18T03:20:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DYNSEO\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DYNSEO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/\"},\"author\":{\"name\":\"DYNSEO\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\"},\"headline\":\"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know\",\"datePublished\":\"2026-06-18T03:17:51+00:00\",\"dateModified\":\"2026-06-18T03:20:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/\"},\"wordCount\":3555,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/abcdhe-5.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/\",\"name\":\"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/abcdhe-5.jpg\",\"datePublished\":\"2026-06-18T03:17:51+00:00\",\"dateModified\":\"2026-06-18T03:20:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/abcdhe-5.jpg\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/abcdhe-5.jpg\",\"width\":1024,\"height\":576,\"caption\":\"Unlocking the Potential of Childhood with Therapeutic Tablets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"name\":\"Jeux de m\u00e9moire et stimulation cognitive\",\"description\":\"DYNSEO, and your brain is a new hero!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"width\":5073,\"height\":1397,\"caption\":\"DYNSEO\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/author\\\/justine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/","og_locale":"en_US","og_type":"article","og_title":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all","og_url":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/","og_site_name":"DYNSEO - Educational apps &amp; brain training apps for all","article_published_time":"2026-06-18T03:17:51+00:00","article_modified_time":"2026-06-18T03:20:53+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg","type":"image\/jpeg"}],"author":"DYNSEO","twitter_misc":{"Written by":"DYNSEO","Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#article","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/"},"author":{"name":"DYNSEO","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6"},"headline":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know","datePublished":"2026-06-18T03:17:51+00:00","dateModified":"2026-06-18T03:20:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/"},"wordCount":3555,"publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/","url":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/","name":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know - DYNSEO - Educational apps &amp; brain training apps for all","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#primaryimage"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg","datePublished":"2026-06-18T03:17:51+00:00","dateModified":"2026-06-18T03:20:53+00:00","breadcrumb":{"@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#primaryimage","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/09\/abcdhe-5.jpg","width":1024,"height":576,"caption":"Unlocking the Potential of Childhood with Therapeutic Tablets"},{"@type":"BreadcrumbList","@id":"https:\/\/www.dynseo.com\/en\/neuroleptics-and-dementia-the-contraindications-every-caregiver-should-know\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dynseo.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neuroleptics and Dementia: The Contraindications Every Caregiver Should Know"}]},{"@type":"WebSite","@id":"https:\/\/www.dynseo.com\/en\/#website","url":"https:\/\/www.dynseo.com\/en\/","name":"Jeux de m\u00e9moire et stimulation cognitive","description":"DYNSEO, and your brain is a new hero!","publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dynseo.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.dynseo.com\/en\/#organization","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","width":5073,"height":1397,"caption":"DYNSEO"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/author\/justine\/"}]}},"_links":{"self":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/708061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/comments?post=708061"}],"version-history":[{"count":9,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/708061\/revisions"}],"predecessor-version":[{"id":708070,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/708061\/revisions\/708070"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media\/410101"}],"wp:attachment":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media?parent=708061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/categories?post=708061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/tags?post=708061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}